SGLT2 inhibitors: towards a personalized prescription

Jean-Baptiste de Freminville^{1

2

3}, Theodora Bejan-Angoulvant^{2

3

4}

Affiliations

¹ Cardiology Department, CHRU Tours, Tours, France.
² Faculty of Medicine, University of Tours, Tours, France.
³ INSERM, UMR 1327, ISCHEMIA "Membrane signaling and inflammation in reperfusion injuries", Tours, France.
⁴ Medical Pharmacology Department, CHRU de Tours, Tours, France.

Editorial

Jean-Baptiste de Freminville et al. Eur J Prev Cardiol. 2025.

. 2025 Apr 15:zwaf220.

doi: 10.1093/eurjpc/zwaf220. Online ahead of print.

Jean-Baptiste de Freminville^{1

2

3}, Theodora Bejan-Angoulvant^{2

3

4}

¹ Cardiology Department, CHRU Tours, Tours, France.
² Faculty of Medicine, University of Tours, Tours, France.
³ INSERM, UMR 1327, ISCHEMIA "Membrane signaling and inflammation in reperfusion injuries", Tours, France.
⁴ Medical Pharmacology Department, CHRU de Tours, Tours, France.

No abstract available

Comment on

Effect of SGLT2i on kidney outcomes of individuals with type2 diabetes according to blood pressure levels.
Jimba T, Kaneko H, Suzuki Y, Okada A, Azegami T, Ko T, Fujiu K, Morita H, Takeda N, Hayashi K, Yokoo T, Node K, Komuro I, Yasunaga H, Nangaku M, Takeda N. Jimba T, et al. Eur J Prev Cardiol. 2025 Mar 18:zwaf156. doi: 10.1093/eurjpc/zwaf156. Online ahead of print. Eur J Prev Cardiol. 2025. PMID: 40100750